Clene's CNM-Au8 Demonstrates Significant Brain Energy Improvement in Multiple Sclerosis Patients at ECTRIMS 2025

Clene Inc. (NASDAQ: CLNN) presented combined results from its REPAIR-MS trial at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona, demonstrating that CNM-Au8 significantly improved brain NAD+/NADH ratios across both relapsing and non-active progressive multiple sclerosis patients. The treatment produced significant changes in brain NAD+ and NADH fractions, with correlations observed between baseline brain energy metabolism and various clinical measures including disability, cognition, and motor function.

The findings represent a potential breakthrough in multiple sclerosis treatment by targeting the underlying bioenergetic failure that contributes to disease progression. CNM-Au8, an investigational first-in-class therapy, works by improving central nervous system cells' survival and function through a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. The treatment was shown to be safe and well tolerated in the trial, reinforcing its potential as a novel therapeutic approach for neurodegenerative diseases.

For investors and the pharmaceutical industry, these results validate Clene's focus on mitochondrial health and neuronal protection as a viable pathway for treating complex neurodegenerative conditions. The company's latest developments can be followed through their newsroom at https://ibn.fm/CLNN. The positive safety profile combined with meaningful biological effects suggests CNM-Au8 could address an unmet need in multiple sclerosis treatment, particularly for patients with progressive forms of the disease where current treatment options remain limited.

The implications of these findings extend beyond multiple sclerosis to other neurodegenerative conditions where mitochondrial dysfunction plays a key role, including amyotrophic lateral sclerosis and Parkinson's disease. By demonstrating measurable improvements in brain energy metabolism, Clene's approach offers a new paradigm for treating neurodegenerative diseases that focuses on enhancing cellular energy production rather than solely targeting inflammatory pathways. Additional information about the company's research and development can be found at https://www.clene.com.

For the multiple sclerosis community, these results offer hope for treatments that could potentially slow or prevent disease progression by addressing fundamental cellular energy deficits. The correlation between improved energy metabolism and clinical outcomes suggests that targeting bioenergetic failure could lead to meaningful improvements in patients' quality of life and functional abilities. The presentation at ECTRIMS 2025, one of the world's premier multiple sclerosis research conferences, provides important validation from the scientific community and positions CNM-Au8 as a promising candidate for further clinical development.